Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.34 |
| ▸ | FABP7 | O15540 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.33 |
| ▸ | ALB | P02768 | 3/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3591991 | 0.83 | CAPN1 (0.40) | CYP1A2CAPN1 | |
| SCHEMBL3583173 | 0.82 | PTPN1 (0.33) | KMT2APTPN1 | |
| SCHEMBL3584475 | 0.81 | KMT2A (0.35) | KMT2AFABP5FABP7CYP1A2TSHR | |
| SCHEMBL3592462 | 0.72 | CTSK (0.38) | CYP1A2 | |
| SCHEMBL29823514 | 0.71 | KMT2A (0.46) | KMT2AFABP5FABP7EPHX2ELANE | |
| SCHEMBL3587892 | 0.70 | PTPN1 (0.39) | KMT2APTPN1 | |
| SCHEMBL8809665 | 0.69 | CAPN1 (0.42) | KMT2APIN1CAPN1 | |
| SCHEMBL4560987 | 0.69 | CAPN1 (0.58) | CAPN1 | |
| SCHEMBL23518037 | 0.67 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2 | |
| SCHEMBL7360658 | 0.67 | KMT2A (0.34) | KMT2AFABP5FABP7EPHX2ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642591-B2 | Composition containing amidine derivatives or carboxamide derivatives and steroids, as a medicament | IPSEN PHARMA S.A.S. (FR) | 2014-02-04 | — | — | US | disclosed |
| EP-1993555-B1 | COMPOSITION CONTAINING AMIDINE DERIVATIVES OR CARBOXAMIDE DERIVATIVES AND STEROIDS, AS A MEDICAMENT | IPSEN PHARMA (FR) | 2012-10-17 | — | — | EP | disclosed |
| EP-1954288-B1 | AMIDINE DERIVATIVES AND THEIR USES AS MEDICINE | IPSEN PHARMA (FR) | 2012-08-01 | — | — | EP | disclosed |
| US-7659266-B2 | Amidine derivatives and their applications as a medicament | S.C.R.A.S. (FR) | 2010-02-09 | — | — | US | disclosed |
| US-20090149430-A1 | COMPOSITION CONTAINING AMIDINE DERIVATIVES OR CARBOXAMIDE DERIVATIVES AND STEROIDS, AS A MEDICAMENT | IPSEN PHARMA S.A.S. (FR) | 2009-06-11 | — | — | US | disclosed |
| US-20090018120-A1 | AMIDINE DERIVATIVES AND THEIR APPLICATIONS AS A MEDICAMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 2009-01-15 | — | — | US | disclosed |
| EP-1993555-A1 | COMPOSITION CONTAINING AMIDINE DERIVATIVES OR CARBOXAMIDE DERIVATIVES AND STEROIDS, AS A MEDICAMENT | Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S) SAS (FR) | 2008-11-26 | — | — | EP | disclosed |
| EP-1954288-A1 | AMIDINE DERIVATIVES AND THEIR USES AS MEDICINE | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007101937-A1 | COMPOSITION CONTAINING AMIDINE DERIVATIVES OR CARBOXAMIDE DERIVATIVES AND STEROIDS, AS A MEDICAMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007045761-A1 | AMIDINE DERIVATIVES AND THEIR USES AS MEDICINE | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149430-A1 | COMPOSITION CONTAINING AMIDINE DERIVATIVES OR CARBOXAMIDE DERIVATIVES AND STEROIDS, AS A MEDICAMENT | MC2R, CYP11B2, NR3C2 | KMT2A 1361/4885FABP5 968/4885FABP7 1207/4885 |
| US-20090018120-A1 | AMIDINE DERIVATIVES AND THEIR APPLICATIONS AS A MEDICAMENT | CAPN2, CAPN9, CAPN1 | KMT2A 4623/4885FABP5 1908/4885FABP7 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.